In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Iovance Biotherapeutics Inc (IOVA), with a price target of $30. The company’s shares opened today at $25, close to its 52-week high of $25.50.
According to TipRanks.com, Livshits is a 4-star analyst with an average return of 27.1% and a 66.7% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Intellia Therapeutics, and Editas Medicine Inc.
Currently, the analyst consensus on Iovance Biotherapeutics Inc is a Strong Buy with an average price target of $30.63, representing a 22.5% upside. In a report issued on June 28, Piper Jaffray also maintained a Buy rating on the stock with a $30 price target.
See today’s analyst top recommended stocks >>
Based on Iovance Biotherapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $36.95 million. In comparison, last year the company had a GAAP net loss of $30.66 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients’ tumors.
